Castle Biosciences, Inc Earning Date (CSTL)

USA |NASDAQ |USD

CSTL Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 8, 2022 Jun 2022 - - $-0.35
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 8, 2022 Jun 2022 - - $22.76M

Castle Biosciences, Inc's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 2022.

CSTL Earnings Date & History Chart

CSTL Earnings & Revenue Forecast

CSTL Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 6 $-1.50 $-2.44 $-0.66

CSTL Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 1 / 0 $-1.45 $-1.11 $-1.11

CSTL Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 6 $113.41M $104.00M $121.10M

CSTL Earnings Date & Revenue History

CSTL Earnings History

|
Show More
Show More

CSTL Revenue History

|
Show More
Show More

Castle Biosciences, Inc Next Earnings Date & Report

CSTL Next Earnings Date & Report Preview: Jun 2022 (FQ)

CSTL's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 30, 2022.

Castle Biosciences, Inc Previous Earnings Dates & Reports

CSTL Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Castle Biosciences, Inc's previous earnings date was May 9, 2022 for its fiscal quarter ended Mar 31, 2022.

CSTL Previous Earnings Date & Report Recap: Dec 2021 (FY)

Castle Biosciences, Inc's previous annual earnings date was Feb 28, 2022 for its fiscal year ended Dec 31, 2021.

CSTL's earnings per share (EPS) was $-1.24, beating the consensus analysts forecast of $-1.47 by -15.65% , and lower than the previous year's EPS (Dec 2020) by 143.14%.

Revenues were $94.08M, better than the forecast of $92.41M by 1.81%, and up by 50.18% from previous year's revenue.

The company reported a net income of $-31.29M.

Castle Biosciences, Inc reported a free cash flow of $-22.47M for its fiscal year, compared to $5.11M a year ago.

The company ended the fiscal year with $16.16M in total debt. lala